Table of Contents Chapter 1 Overview of Hairy Cell Leukemia Therapeutics 1.1 Definition of Hairy Cell Leukemia Therapeutics in This Report 1.2 Commercial Types of Hairy Cell Leukemia Therapeutics 1.2.1 Dezapelisib 1.2.2 ELB-021 1.2.3 Ibrutinib 1.2.4 AGS-67E 1.2.5 ARABS-4 1.2.6 Others 1.3 Downstream Application of Hairy Cell Leukemia Therapeutics 1.3.1 Hospital 1.3.2 Clinic 1.3.3 Others 1.4 Development History of Hairy Cell Leukemia Therapeutics 1.5 Market Status and Trend of Hairy Cell Leukemia Therapeutics 2013-2023 1.5.1 EMEA Hairy Cell Leukemia Therapeutics Market Status and Trend 2013-2023 1.5.2 Regional Hairy Cell Leukemia Therapeutics Market Status and Trend 2013-2023 Chapter 2 EMEA Market Status and Forecast by Regions 2.1 Market Status of Hairy Cell Leukemia Therapeutics in EMEA 2013-2017 2.2 Consumption Market of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2.2.1 Consumption Volume of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2.2.2 Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2.3 Market Analysis of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2.3.1 Market Analysis of Hairy Cell Leukemia Therapeutics in Europe 2013-2017 2.3.2 Market Analysis of Hairy Cell Leukemia Therapeutics in Middle East 2013-2017 2.3.3 Market Analysis of Hairy Cell Leukemia Therapeutics in Africa 2013-2017 2.4 Market Development Forecast of Hairy Cell Leukemia Therapeutics in EMEA 2018-2023 2.4.1 Market Development Forecast of Hairy Cell Leukemia Therapeutics in EMEA 2018-2023 2.4.2 Market Development Forecast of Hairy Cell Leukemia Therapeutics by Regions 2018-2023 Chapter 3 EMEA Market Status and Forecast by Types 3.1 Whole EMEA Market Status by Types 3.1.1 Consumption Volume of Hairy Cell Leukemia Therapeutics in EMEA by Types 3.1.2 Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Types 3.2 EMEA Market Status by Types in Major Countries 3.2.1 Market Status by Types in Europe 3.2.2 Market Status by Types in Middle East 3.2.3 Market Status by Types in Africa 3.3 Market Forecast of Hairy Cell Leukemia Therapeutics in EMEA by Types Chapter 4 EMEA Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Hairy Cell Leukemia Therapeutics in EMEA by Downstream Industry 4.2 Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Major Countries 4.2.1 Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Europe 4.2.2 Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Middle East 4.2.3 Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Africa 4.3 Market Forecast of Hairy Cell Leukemia Therapeutics in EMEA by Downstream Industry Chapter 5 Market Driving Factor Analysis of Hairy Cell Leukemia Therapeutics 5.1 EMEA Economy Situation and Trend Overview 5.2 Hairy Cell Leukemia Therapeutics Downstream Industry Situation and Trend Overview Chapter 6 Hairy Cell Leukemia Therapeutics Market Competition Status by Major Players in EMEA 6.1 Sales Volume of Hairy Cell Leukemia Therapeutics in EMEA by Major Players 6.2 Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Major Players 6.3 Basic Information of Hairy Cell Leukemia Therapeutics by Major Players 6.3.1 Headquarters Location and Established Time of Hairy Cell Leukemia Therapeutics Major Players 6.3.2 Employees and Revenue Level of Hairy Cell Leukemia Therapeutics Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Hairy Cell Leukemia Therapeutics Major Manufacturers Introduction and Market Data 7.1 AbbVie Inc 7.1.1 Company profile 7.1.2 Representative Hairy Cell Leukemia Therapeutics Product 7.1.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie Inc 7.2 ARA Healthcare Pvt Ltd 7.2.1 Company profile 7.2.2 Representative Hairy Cell Leukemia Therapeutics Product 7.2.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of ARA Healthcare Pvt Ltd 7.3 Astellas Pharma Inc. 7.3.1 Company profile 7.3.2 Representative Hairy Cell Leukemia Therapeutics Product 7.3.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc. 7.4 Cellectis SA 7.4.1 Company profile 7.4.2 Representative Hairy Cell Leukemia Therapeutics Product 7.4.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Cellectis SA 7.5 F. Hoffmann-La Roche Ltd 7.5.1 Company profile 7.5.2 Representative Hairy Cell Leukemia Therapeutics Product 7.5.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 7.6 Incyte Corp 7.6.1 Company profile 7.6.2 Representative Hairy Cell Leukemia Therapeutics Product 7.6.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Incyte Corp 7.7 Juno Therapeutics Inc 7.7.1 Company profile 7.7.2 Representative Hairy Cell Leukemia Therapeutics Product 7.7.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Juno Therapeutics Inc 7.8 MedImmune LLC 7.8.1 Company profile 7.8.2 Representative Hairy Cell Leukemia Therapeutics Product 7.8.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of MedImmune LLC 7.9 Novartis AG 7.9.1 Company profile 7.9.2 Representative Hairy Cell Leukemia Therapeutics Product 7.9.3 Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Novartis AG Chapter 8 Upstream and Downstream Market Analysis of Hairy Cell Leukemia Therapeutics 8.1 Industry Chain of Hairy Cell Leukemia Therapeutics 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Hairy Cell Leukemia Therapeutics 9.1 Cost Structure Analysis of Hairy Cell Leukemia Therapeutics 9.2 Raw Materials Cost Analysis of Hairy Cell Leukemia Therapeutics 9.3 Labor Cost Analysis of Hairy Cell Leukemia Therapeutics 9.4 Manufacturing Expenses Analysis of Hairy Cell Leukemia Therapeutics Chapter 10 Marketing Status Analysis of Hairy Cell Leukemia Therapeutics 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Dezapelisib Table Advantage and Disadvantage of ELB-021 Table Advantage and Disadvantage of Ibrutinib Table Advantage and Disadvantage of AGS-67E Table Advantage and Disadvantage of ARABS-4 Table Advantage and Disadvantage of Others Table Consumption Volume of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2013-2017 Table Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2013-2017 Table Consumption Volume of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2018-2023 Table Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Regions 2018-2023 Table Consumption Volume of Hairy Cell Leukemia Therapeutics in EMEA by Types 2013-2017 Table Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Types 2013-2017 Table Consumption Volume of Hairy Cell Leukemia Therapeutics by Types in Europe 2013-2017 Table Consumption Volume of Hairy Cell Leukemia Therapeutics by Types in Middle East 2013-2017 Table Consumption Volume of Hairy Cell Leukemia Therapeutics by Types in Africa 2013-2017 Table Consumption Volume Forecast of Hairy Cell Leukemia Therapeutics in EMEA by Types 2018-2023 Table Revenue Forecast of Hairy Cell Leukemia Therapeutics in EMEA by Types 2018-2023 Table Demand Volume of Hairy Cell Leukemia Therapeutics in EMEA by Downstream Industry 2013-2017 Table Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Europe 2013-2017 Table Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Middle East 2013-2017 Table Demand Volume of Hairy Cell Leukemia Therapeutics by Downstream Industry in Africa 2013-2017 Table Demand Volume Forecast of Hairy Cell Leukemia Therapeutics in EMEA by Downstream Industry 2018-2023 Table Sales Volume of Hairy Cell Leukemia Therapeutics in EMEA by Major Players 2013-2017 Table Revenue of Hairy Cell Leukemia Therapeutics in EMEA by Major Players 2013-2017 Table Headquarters Location and Established Time of Hairy Cell Leukemia Therapeutics Major Players Table Employees and Revenue Level of Hairy Cell Leukemia Therapeutics Major Players Table Representative Hairy Cell Leukemia Therapeutics Product One of AbbVie Inc Table Representative Hairy Cell Leukemia Therapeutics Product Two of AbbVie Inc Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie Inc 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of ARA Healthcare Pvt Ltd Table Representative Hairy Cell Leukemia Therapeutics Product Two of ARA Healthcare Pvt Ltd Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of ARA Healthcare Pvt Ltd 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of Astellas Pharma Inc. Table Representative Hairy Cell Leukemia Therapeutics Product Two of Astellas Pharma Inc. Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc. 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of Cellectis SA Table Representative Hairy Cell Leukemia Therapeutics Product Two of Cellectis SA Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Cellectis SA 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of F. Hoffmann-La Roche Ltd Table Representative Hairy Cell Leukemia Therapeutics Product Two of F. Hoffmann-La Roche Ltd Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of Incyte Corp Table Representative Hairy Cell Leukemia Therapeutics Product Two of Incyte Corp Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Incyte Corp 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of Juno Therapeutics Inc Table Representative Hairy Cell Leukemia Therapeutics Product Two of Juno Therapeutics Inc Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Juno Therapeutics Inc 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of MedImmune LLC Table Representative Hairy Cell Leukemia Therapeutics Product Two of MedImmune LLC Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of MedImmune LLC 2013-2017 Table Representative Hairy Cell Leukemia Therapeutics Product One of Novartis AG Table Representative Hairy Cell Leukemia Therapeutics Product Two of Novartis AG Table Hairy Cell Leukemia Therapeutics Sales, Revenue, Price and Gross Margin of Novartis AG 2013-2017